Lutein Ophthalmic Composition Viscosity Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome, such as artificial tears and anti-inflammatory drugs, have short retention times on the ocular surface and can cause side effects, leading to delayed therapeutic effects and discomfort, while lutein supplementation from food has low bioavailability due to the blood-retina barrier.
Innovation Solution
A lutein-containing ophthalmic composition combining lutein with polyvinyl alcohol (PVA) to increase viscosity and retention time on the ocular surface, allowing for direct administration and enhanced anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If artificial tears and anti-inflammatory drugs are administered via topical delivery, then the ocular surface is treated, but the retention time on the ocular surface is short leading to delayed therapeutic effect
Solution Approach 1:
The patent changes the physical parameter of viscosity by adding polyvinyl alcohol to the ophthalmic composition. This increases the retention time of the composition on the ocular surface, allowing lutein to remain in contact with the eye longer and achieve therapeutic effects without frequent reapplication.
Solution Approach 2:
The patent creates a composite ophthalmic composition combining lutein (anti-inflammatory substance) with polyvinyl alcohol (viscosity-enhancing polymer) and artificial tear components. This composite formulation provides both therapeutic action and extended residence time on the ocular surface.
2Reliability
If anti-inflammatory drugs are used, then inflammation is reduced, but side effects such as vision blurred and mobility difficulty occur
Solution Approach 1:
The patent uses lutein, a natural carotenoid with anti-inflammatory properties that can be administered topically without the severe side effects of conventional anti-inflammatory drugs. While lutein itself is not long-lasting, the polyvinyl alcohol extends its residence time, providing sustained anti-inflammatory action with minimal side effects.
Solution Approach 2:
The patent changes the chemical nature of the anti-inflammatory agent from conventional drugs (steroids or NSAIDs) to lutein, a natural carotenoid. This substitution reduces harmful side effects while maintaining anti-inflammatory efficacy, particularly for ocular surface inflammation and dry eye syndrome.
3Quantity of substance
If lutein is supplemented from food, then lutein is ingested, but bioavailability is low due to the blood-retina barrier
Solution Approach 1:
The patent uses topical administration as an intermediary pathway to deliver lutein directly to the ocular surface, bypassing the blood-retina barrier that limits bioavailability from oral ingestion. This direct delivery method ensures sufficient lutein concentration reaches the target site without relying on systemic circulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prolongs the retention of anti-inflammatory substances on the ocular surface, reducing inflammation and improving dry eye syndrome symptoms, while also protecting the retina and preventing retinopathy.
Implementation Method 1
polyvinyl alcohol (PVA) as a substance which is increasing liquid viscosity
Data Source
Figure 1~2
Figure 3A~3B
Figure 3C~4
AI summary
A lutein-containing ophthalmic composition, wherein the ophthalmic composition is mainly consisting of a natural anti-inflammatory substance, a substance with increasing liquid viscosity, and an artificial tear. The substance with increasing liquid viscosity could apply the ophthalmic composition to elongate the retention time on the ocular surface, thereby increasing the retention time of anti-inflammatory substance on the ocular surface for treating dry eye syndrome and inhibiting ocular surface inflammation.